新型糖肽类抗生素去甲普兰宁（M86-1410）的体外活性
In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.
作者信息
Sanchez M L, Wenzel R P, Jones R N
机构信息
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
出版信息
Antimicrob Agents Chemother. 1992 Apr;36(4):873-5. doi: 10.1128/AAC.36.4.873.
Abstract
The in vitro activity of decaplanin (formerly M86-1410), a novel glycopeptide antimicrobial agent, was tested against 169 gram-positive bloodstream isolates from patients at the University of Iowa Hospitals and Clinics and 12 selected vancomycin-resistant strains. Enterococcus faecalis, E. faecium, Staphylococcus aureus, streptococci, bacilli, corynebacteria, and listeria were inhibited by decaplanin (MICs for 90% of the strains tested [MIC90s], 0.12 to 4 micrograms/ml). However, some rarely isolated and selected Enterococcus sp. populations had a MIC90 of 16 micrograms/ml, and S. haemolyticus strains had a MIC90 of 8 micrograms/ml. These in vitro results suggest that decaplanin may be useful against most gram-positive strains, even though some Enterococcus species and coagulase-negative staphylococci were potentially resistant (MICs, greater than or equal to 8 micrograms/ml).
摘要
新型糖肽类抗菌药物去甲万古霉素（原名M86 - 1410）的体外活性，针对爱荷华大学医院和诊所患者的169株革兰氏阳性血流分离株以及12株选定的耐万古霉素菌株进行了测试。粪肠球菌、屎肠球菌、金黄色葡萄球菌、链球菌、芽孢杆菌、棒状杆菌和李斯特菌均被去甲万古霉素抑制（90%受试菌株的最低抑菌浓度[MIC90]为0.12至4微克/毫升）。然而，一些罕见分离和选定的肠球菌种群的MIC90为16微克/毫升，溶血葡萄球菌菌株的MIC90为8微克/毫升。这些体外结果表明，去甲万古霉素可能对大多数革兰氏阳性菌株有效，尽管一些肠球菌属和凝固酶阴性葡萄球菌可能具有耐药性（MIC大于或等于8微克/毫升）。
相似文献
1
In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.新型糖肽类抗生素去甲普兰宁（M86-1410）的体外活性
Antimicrob Agents Chemother. 1992 Apr;36(4):873-5. doi: 10.1128/AAC.36.4.873.
2
In vitro activity of the new glycopeptide decaplanin.
Eur J Clin Microbiol Infect Dis. 1992 May;11(5):458-62. doi: 10.1007/BF01961864.
3
European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.1995年革兰氏阳性菌的欧洲糖肽敏感性调查。欧洲糖肽耐药性调查研究组。
Diagn Microbiol Infect Dis. 1998 Aug;31(4):563-71. doi: 10.1016/s0732-8893(98)00053-4.
4
In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.新型糖肽类抗生素LY264826对从癌症患者中分离出的革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1990 Nov;34(11):2137-41. doi: 10.1128/AAC.34.11.2137.
5
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素，对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
6
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.一种新型糖肽类抗生素（LY333328）对肠球菌及其他耐药革兰氏阳性菌的活性。
J Antimicrob Chemother. 1997 Sep;40(3):423-5. doi: 10.1093/jac/40.3.423.
7
Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.意大利临床实验室运用常规实验室方法检测肠球菌和葡萄球菌属中糖肽敏感性降低情况的能力。
Clin Microbiol Infect. 2002 Feb;8(2):101-11. doi: 10.1046/j.1469-0691.2002.00378.x.
8
Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility.德国住院患者中肠球菌属和凝固酶阴性葡萄球菌的糖肽类耐药性：发生率、特征及达巴万星敏感性
J Glob Antimicrob Resist. 2022 Mar;28:102-107. doi: 10.1016/j.jgar.2021.12.016. Epub 2021 Dec 25.
9
Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.糖肽类抗生素体外耐药性的产生：不同种葡萄球菌中的评估
J Antimicrob Chemother. 1991 Jan;27(1):71-9. doi: 10.1093/jac/27.1.71.
10
Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.达托霉素和替考拉宁对溶血葡萄球菌和表皮葡萄球菌的活性，包括药敏试验建议的评估。
Antimicrob Agents Chemother. 1989 Apr;33(4):585-8. doi: 10.1128/AAC.33.4.585.
引用本文的文献
1
Glycopeptide Antibiotic Resistance Genes: Distribution and Function in the Producer Actinomycetes.糖肽类抗生素抗性基因：在产生放线菌中的分布与功能
Front Microbiol. 2020 Jun 17;11:1173. doi: 10.3389/fmicb.2020.01173. eCollection 2020.
2
Diversity of monomers in nonribosomal peptides: towards the prediction of origin and biological activity.非核糖体肽中单体的多样性：走向起源和生物活性的预测。
J Bacteriol. 2010 Oct;192(19):5143-50. doi: 10.1128/JB.00315-10. Epub 2010 Aug 6.
3
Vancomycin-resistant enterococci.耐万古霉素肠球菌
Clin Microbiol Rev. 2000 Oct;13(4):686-707. doi: 10.1128/CMR.13.4.686.
4
Management of listeriosis.李斯特菌病的管理
Clin Microbiol Rev. 1997 Apr;10(2):345-57. doi: 10.1128/CMR.10.2.345.
5
Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus.在金黄色葡萄球菌中，一种与万古霉素耐药性相关的、与NAD⁺连接的D - 乳酸脱氢酶同源的37千道尔顿细胞质蛋白产生过量。
Antimicrob Agents Chemother. 1996 Jan;40(1):166-72. doi: 10.1128/AAC.40.1.166.
6
Current perspectives on glycopeptide resistance.糖肽类耐药性的当前观点
Clin Microbiol Rev. 1995 Oct;8(4):585-615. doi: 10.1128/CMR.8.4.585.
7
Update on clinical significance of coagulase-negative staphylococci.凝固酶阴性葡萄球菌临床意义的最新进展
Clin Microbiol Rev. 1994 Jan;7(1):117-40. doi: 10.1128/CMR.7.1.117.
本文引用的文献
1
The antibacterial action of vancomycin.万古霉素的抗菌作用。
Rev Infect Dis. 1981 Nov-Dec;3 suppl:S210-5.
2
Gram-positive infections in granulocytopenic patients: an important issue?
J Antimicrob Chemother. 1988 Apr;21 Suppl C:149-56. doi: 10.1093/jac/21.suppl_c.149.
3
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.糖肽类药物对耐万古霉素革兰氏阳性菌的活性。
Antimicrob Agents Chemother. 1989 Sep;33(9):1477-81. doi: 10.1128/AAC.33.9.1477.
4
Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem?对青霉素和氨苄西林高度耐药的肠球菌：一个新出现的临床问题？
J Clin Microbiol. 1989 Sep;27(9):2091-5. doi: 10.1128/jcm.27.9.2091-2095.1989.
5
Identification of Enterococcus species isolated from human infections by a conventional test scheme.通过传统检测方案鉴定从人类感染中分离出的肠球菌种类。
J Clin Microbiol. 1989 Apr;27(4):731-4. doi: 10.1128/jcm.27.4.731-734.1989.
6
In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.耐万古霉素粪肠球菌的体外药敏研究。
Antimicrob Agents Chemother. 1989 Sep;33(9):1588-91. doi: 10.1128/AAC.33.9.1588.
7
Characterization of vancomycin resistance in Enterococcus faecium and Enterococcus faecalis.粪肠球菌和屎肠球菌中万古霉素耐药性的特征分析
Antimicrob Agents Chemother. 1989 Jul;33(7):1121-4. doi: 10.1128/AAC.33.7.1121.
8
Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection.溶血葡萄球菌中引起定植和血流感染的万古霉素耐药性。
J Clin Microbiol. 1990 Sep;28(9):2064-8. doi: 10.1128/jcm.28.9.2064-2068.1990.
9
Resistance to vancomycin and teicoplanin: an emerging clinical problem.对万古霉素和替考拉宁的耐药性：一个新出现的临床问题。
Clin Microbiol Rev. 1990 Jul;3(3):280-91. doi: 10.1128/CMR.3.3.280.
10
In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients.万古霉素和替考拉宁对从中性粒细胞减少患者中分离出的凝固酶阴性葡萄球菌的体外活性。
Antimicrob Agents Chemother. 1990 May;34(5):901-3. doi: 10.1128/AAC.34.5.901.
Zotero 插件